MHRA approves Pfizer-BioNTech vaccine for the UK, will be available from next week

2 min read | December 02, 2020 08:21 AM GMT | By Kunal Sawhney

In a historic development, the Medicines and Healthcare Products Regulatory Authority (MHRA) of the United Kingdom has given approval to the Pfizer-BioNTech vaccine. With this, the UK has become the first western country ahead of the US and Europe to approve a vaccine for mass immunisation. The MHRA was given the power to approve a suitable vaccine by the Boris Johnson government under special regulations before 1 January.

In a statement, the government has said that the vaccine will be available in the UK from next week. The UK has already bought 40 million doses. The vaccine which has to be kept at -70C, as per the company, can be stored for up to five days in a fridge, at an average temperature of 2 to 8°C.

A government spokesperson has said that the experts at MHRA have conducted various studies and concluded that the vaccine was apt and has met its strict standards of safety, quality and effectiveness.

He added that the MHRA officials would soon issue the next advisory on the vaccination process and the priority groups who would receive the vaccine. The first priority group includes care home residents, health and care staff, the elderly and others who are extremely vulnerable.

Earlier, Pfizer-BioNTech had claimed that their Covid-19 vaccine was safe and had 95 per cent efficacy and has claimed that it works well for older people who are most at risk of fatality due to the disease. Its final result had shown that in the final trial only eight of the 20,000 people who were given the vaccine got infected due to the coronavirus.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next